Your browser doesn't support javascript.
loading
Oral ulcers and sarcoid-like reaction in lymph nodes after cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma: a case report
Ferreira, Mariana Henriques; Bezinelli, Letícia Mello; Eduardo, Fernanda de Paula; Gobbi, Marcella Ferreira; Corrêa, Luciana; Schvartsman, Gustavo.
  • Ferreira, Mariana Henriques; Hospital Israelita Albert Einstein. São Paulo. BR
  • Bezinelli, Letícia Mello; Hospital Israelita Albert Einstein. São Paulo. BR
  • Eduardo, Fernanda de Paula; Hospital Israelita Albert Einstein. São Paulo. BR
  • Gobbi, Marcella Ferreira; Hospital Israelita Albert Einstein. São Paulo. BR
  • Corrêa, Luciana; Universidade de São Paulo. Faculdade de Odontologia. BR
  • Schvartsman, Gustavo; Hospital Israelita Albert Einstein. São Paulo. BR
Einstein (Säo Paulo) ; 20: eRC6367, 2022. tab, graf
Article in English | LILACS | ID: biblio-1364787
ABSTRACT
ABSTRACT Cemiplimab is a novel programmed death-1 inhibitor recently approved for advanced cutaneous squamous cell carcinoma. Immune-related adverse events derived from cemiplimab are similar to other anti-PD-1 drugs, including gastrointestinal and cutaneous toxicities. Oral immune-related adverse events were not reported with cemiplimab in previous studies; thus this case report warns of the fact that the oral cavity may be a site of immune-related adverse events during programmed death-1 block therapy and that this can lead to significant limitations when not properly treated. The present report describes the case of a patient with locally advanced cutaneous squamous cell carcinoma metastatic to cervical lymph nodes who developed dysphagia due to large and painful oral ulcers after a single dose of cemiplimab. The patient also exhibited a sarcoid-like reaction in mediastinal lymph nodes. No immune-related adverse events were found in any other organs. The oral lesions showed significant improvement after topical and short-course systemic corticosteroids, and low-level laser therapy was also performed in the oral lesions. The patient achieved a near-complete response and treatment was discontinued. This article discusses in detail the clinical outcomes and oral toxicity management of cemiplimab therapy for cutaneous squamous cell carcinoma.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Skin Neoplasms / Carcinoma, Squamous Cell / Oral Ulcer Limits: Humans Language: English Journal: Einstein (Säo Paulo) Journal subject: Medicine Year: 2022 Type: Article Affiliation country: Brazil Institution/Affiliation country: Hospital Israelita Albert Einstein/BR / Universidade de São Paulo/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Skin Neoplasms / Carcinoma, Squamous Cell / Oral Ulcer Limits: Humans Language: English Journal: Einstein (Säo Paulo) Journal subject: Medicine Year: 2022 Type: Article Affiliation country: Brazil Institution/Affiliation country: Hospital Israelita Albert Einstein/BR / Universidade de São Paulo/BR